Administration per os of 2 X 10(6) fluorescent cell-forming units of a human serotype 3 rotavirus (RV-3) protected all of nine gnotobiotic piglets against severe diarrheal disease when they were challenged 10 to 14 days later with 8 X 10(3) fluorescent cell-forming units of virulent wild-type porcine rotavirus (AT/76). The porcine virus was similar antigenically to porcine prototype strain OSU, previously described as antigenically distinct from all four recognized human serotypes. Administration of RV-3 was associated with the development of serum-neutralizing antibody to both RV-3 and AT/76 in piglets that excreted RV-3. Neutralizing antibody levels to RV-3 and AT/76 increased rapidly postchallenge. Vaccinated piglets were not immune to infection with AT/76 but showed no or minimal gastrointestinal symptoms after challenge. Control nonvaccinated piglets that were fed AT/76 developed severe dehydrating diarrhea and low levels of neutralizing antibody to AT/76 alone. The apparent heterologous clinical protection observed in this study could have been predicted from results of in vitro assays. Neutralization tests with reduction of fluorescence focus indicated a one-way cross-reaction between RV-3 and AT/76 such that hyperimmune antiserum to RV-3 neutralized porcine virus to moderate titer, but not vice versa. The results emphasize the importance of neutralizing antibody in protection against disease and the need to determine reciprocal cross-neutralization titers, rather than serotype alone, in order to predict the ability of rotavirus strains to cross protect.